Detalhe da pesquisa
1.
A replicating LCMV-based vaccine for the treatment of solid tumors.
Mol Ther
; 32(2): 426-439, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38058126
2.
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the ß2 and ß1 subunits of the proteasome complex.
Haematologica
; 108(6): 1628-1639, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36727403
3.
Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.
Eur J Haematol
; 104(3): 190-197, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31763708
4.
HIV protease inhibitors for the treatment of multiple myeloma.
Clin Adv Hematol Oncol
; 17(11): 615-623, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31851164
5.
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
BJU Int
; 121(4): 600-609, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29161753
6.
Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients.
Klin Onkol
; 31(3): 213-229, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30441975
7.
Cell-free DNA - Minimally invasive marker of hematological malignancies.
Eur J Haematol
; 99(4): 291-299, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28692178
8.
Cytogenetics in multiple myeloma patients progressing into extramedullary disease.
Eur J Haematol
; 97(1): 93-100, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26432667
9.
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Blood
; 132(19): 2097-2100, 2018 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30237154
10.
MicroRNAs in urine are not biomarkers of multiple myeloma.
J Negat Results Biomed
; 14: 16, 2015 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-26399230
11.
A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.
Haematologica
; 104(9): e415-e419, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30792209
12.
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Sci Rep
; 13(1): 4411, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932175
13.
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Exp Hematol Oncol
; 12(1): 71, 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37563685
14.
Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Front Oncol
; 12: 899272, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35692781
15.
Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
Cells
; 11(5)2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35269460
16.
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Nat Commun
; 13(1): 4121, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35840578
17.
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells.
Hemasphere
; 5(7): e602, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34136753
18.
High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
Cells
; 10(11)2021 10 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34831075
19.
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.
Blood Adv
; 5(20): 4125-4139, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34478517
20.
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
Cancer Res
; 81(17): 4581-4593, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158378